# Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

> **NCT02493946** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 600 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02493946
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-10
- **Final completion:** 2016-12
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493946, "Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02493946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*